Table 4A.

Multiple regression models for flow-mediated dilatation (in %) in CKD male patients: Total testosterone

Unadjusted (β, P) (r2 = 0.32)Model 1 (β, P) (r2 = 0.33)Model 2 (β, P) (r2 = 0.72)Model 3 (β, P) (r2 = 0.77)
Total testosterone (nmol/L)0.57 (<0.001)0.55 (<0.001)0.26 (<0.001)0.25 (<0.001)
Age (years)−0.01 (0.88)0.02 (0.49)0.02 (0.62)
BMI (kg/m2)0.10 (0.06)0.01 (0.60)0.01 (0.70)
Total cholesterol (nmol/L)−0.01 (0.08)−0.05 (0.12)−0.03 (0.31)
Diabetes (presence)−0.06 (0.23)−0.10 (0.007)−0.10 (0.006)
Previous CVD (presence)0.01 (0.90)−0.02 (0.64)−0.01 (0.57)
Systolic BP (mmHg)−0.03 (0.59)−0.10 (0.005)−0.08 (0.02)
Diastolic BP (mmHg)−0.02 (0.70)0.03 (0.33)0.02 (0.61)
Smoking (yes)−0.09 (0.13)−0.07 (0.04)−0.06 (0.07)
eGFR (ml/min per 1.73 m2)0.68 (<0.001)0.47 (<0.001)
Proteinuria (g/day)−0.02 (0.48)0.01 (0.79)
CRP (mg/L)0.09 (0.08)
Albumin (g/dl)0.10 (0.008)
Serum calcium (mg/dl)−0.02 (0.56)
Serum phosphate (mg/dl)−0.01 (0.77)
PTH (pg/ml)−0.31 (<0.001)
  • CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; CVD, cardiovascular disease; BMI, body mass index; CRP, C-reactive protein; PTH, parathyroid hormone.